Cargando…

Nuclear survivin expression is a positive prognostic factor in taxane-platinum-treated ovarian cancer patients

BACKGROUND: Survivin is an inhibitor of apoptosis and a regulator of mitotic progression. TP53 protein is a negative transcriptional regulator of survivin. The aim of our study was to evaluate the clinical significance of survivin expression in advanced stages ovarian cancer with respect to the TP53...

Descripción completa

Detalles Bibliográficos
Autores principales:	Felisiak-Golabek, Anna, Rembiszewska, Alina, Rzepecka, Iwona K, Szafron, Lukasz, Madry, Radoslaw, Murawska, Magdalena, Napiorkowski, Tomasz, Sobiczewski, Piotr, Osuch, Beata, Kupryjanczyk, Jolanta
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2011
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3223127/ https://www.ncbi.nlm.nih.gov/pubmed/22075440 http://dx.doi.org/10.1186/1757-2215-4-20

Ejemplares similares

Cyclooxygenase-2 immunohistochemical expression in serrated polyps of the colon
por: Kiedrowski, Miroslaw, et al.
Publicado: (2014)

TP53 status and taxane-platinum versus platinum-based therapy in ovarian cancer patients: A non-randomized retrospective study
por: Kupryjanczyk, Jolanta, et al.
Publicado: (2008)

Clinical importance of FANCD2, BRIP1, BRCA1, BRCA2 and FANCF expression in ovarian carcinomas
por: Moes-Sosnowska, Joanna, et al.
Publicado: (2019)

Cytoplasmic HAX1 Is an Independent Risk Factor for Breast Cancer Metastasis
por: Trebinska-Stryjewska, Alicja, et al.
Publicado: (2019)

Germline SMARCA4 mutations in patients with ovarian small cell carcinoma of hypercalcemic type
por: Moes-Sosnowska, Joanna, et al.
Publicado: (2015)

Clinical importance of the EMSY gene expression and polymorphisms in ovarian cancer
por: Dansonka-Mieszkowska, Agnieszka, et al.
Publicado: (2018)

The Novel Gene CRNDE Encodes a Nuclear Peptide (CRNDEP) Which Is Overexpressed in Highly Proliferating Tissues
por: Szafron, Lukasz Michal, et al.
Publicado: (2015)

Hypersensitivity Reactions to Platinum Agents and Taxanes
por: Tsao, Lulu R., et al.
Publicado: (2021)

PROM1, CXCL8, RUNX1, NAV1 and TP73 genes as independent markers predictive of prognosis or response to treatment in two cohorts of high-grade serous ovarian cancer patients
por: Dansonka-Mieszkowska, Agnieszka, et al.
Publicado: (2022)

HAX-1 overexpression, splicing and cellular localization in tumors
por: Trebinska, Alicja, et al.
Publicado: (2010)

Platinum drugs and taxanes: can we overcome resistance?
por: Sazonova, Elena V., et al.
Publicado: (2021)

Evaluation of selected ultrasonographic parameters and marker levels in the preoperative differentiation of borderline ovarian tumors and ovarian cancers
por: Sobiczewski, Piotr, et al.
Publicado: (2012)

Taxanes and platinum derivatives impair Schwann cells via distinct mechanisms
por: Imai, Satoshi, et al.
Publicado: (2017)

Comprehensive review on how platinum- and taxane-based chemotherapy of ovarian cancer affects biology of normal cells
por: Mikuła-Pietrasik, Justyna, et al.
Publicado: (2018)

Evaluation of clinical significance of TP53, BCL-2, BAX and MEK1 expression in 229 ovarian carcinomas treated with platinum-based regimen
por: Kupryjańczyk, J, et al.
Publicado: (2003)

Palliative chemotherapy in carcinoma penis: Does platinum and taxane combination holds a promise?
por: Patil, Vijay M, et al.
Publicado: (2014)

Determination of BRCAness Phenotype in Breast Tumors for the Appointment of Neoadjuvant Chemotherapy Based on Platinum and Taxanes
por: Tsyganov, Matvey Mihajlovich, et al.
Publicado: (2022)

Low-dose-intensity bevacizumab with weekly irinotecan for platinum- and taxanes-resistant epithelial ovarian cancer
por: Liu, Ying, et al.
Publicado: (2015)

Risk factors for chemotherapy‐induced peripheral neuropathy in patients receiving taxane‐ and platinum‐based chemotherapy
por: Molassiotis, Alex, et al.
Publicado: (2019)

Gene Expression Analysis in Ovarian Cancer – Faults and Hints from DNA Microarray Study
por: Lisowska, Katarzyna Marta, et al.
Publicado: (2014)

Circulating Survivin Protein Levels in Lung Cancer Patients Treated With Platinum-Based Chemotherapy
por: Puskas, Rita, et al.
Publicado: (2021)

Effects of platinum/taxane based chemotherapy on acute perfusion in human pelvic tumours measured by dynamic MRI
por: Lankester, K J, et al.
Publicado: (2005)

Vinorelbine Plus Platinum in Patients with Metastatic Triple Negative Breast Cancer and Prior Anthracycline and Taxane Treatment
por: li, Meiying, et al.
Publicado: (2015)

Measurement properties of brief neuropathy screening items in cancer patients receiving taxanes, platinums, or proteasome inhibitors
por: Knoerl, Robert, et al.
Publicado: (2021)

Comparison of Efficacy and Safety of Taxanes Plus Platinum and Fluorouracil Plus Platinum in the First-Line Treatment of Esophageal Cancer: A Systematic Review and Meta-Analysis
por: Zhao, Yue, et al.
Publicado: (2022)

Adjuvant therapy of endometrial cancer: “taxane or not taxane, this is the question”
por: Lorusso, Vito, et al.
Publicado: (2019)

Overexpression of Class III β-tubulin, Sox2, and nuclear Survivin is predictive of taxane resistance in patients with stage III ovarian epithelial cancer
por: Du, Jintong, et al.
Publicado: (2015)

Aberrant Promoter Methylation of Caveolin-1 Is Associated with Favorable Response to Taxane-Platinum Combination Chemotherapy in Advanced NSCLC
por: Brodie, Seth A., et al.
Publicado: (2014)

Survival benefit of taxane plus platinum in recurrent ovarian cancer with non-clear cell, non-mucinous histology
por: Kajiyama, Hiroaki, et al.
Publicado: (2014)

Phase Ib study of irinotecan and ramucirumab for advanced gastric cancer previously treated with fluoropyrimidine with/without platinum and taxane
por: Satake, Hironaga, et al.
Publicado: (2018)

Maintenance chemotherapy after 6 cycles of platinum-doublet regimen in anthracycline-and taxane-pretreated metastatic breast cancer
por: Joung, Eun Kyo, et al.
Publicado: (2021)

Platinum and Taxane Based Adjuvant and Neoadjuvant Chemotherapy in Early Triple-Negative Breast Cancer: A Narrative Review
por: Tian, Hao, et al.
Publicado: (2021)

Unsupervised analysis reveals two molecular subgroups of serous ovarian cancer with distinct gene expression profiles and survival
por: Lisowska, Katarzyna M., et al.
Publicado: (2016)

The significance of c.690G>T polymorphism (rs34529039) and expression of the CEBPA gene in ovarian cancer outcome
por: Konopka, Bozena, et al.
Publicado: (2016)

Prognostic Factors of Second and Third Line Chemotherapy Using 5-FU with Platinum, Irinotecan, and Taxane for Advanced Gastric Cancer
por: Park, Ji Soo, et al.
Publicado: (2011)

Evaluation of survival benefits by platinums and taxanes for an unfavourable subset of carcinoma of unknown primary: a systematic review and meta-analysis
por: Lee, J, et al.
Publicado: (2013)

Effects triggered by platinum nanoparticles on primary keratinocytes
por: Konieczny, Piotr, et al.
Publicado: (2013)

Percutaneous nephrostomy for symptomatic hypermobile kidney: a single centre experience
por: Starownik, Radosław, et al.
Publicado: (2014)

The Potential of Ginkgo biloba as a Source of Biologically Active Compounds—A Review of the Recent Literature and Patents
por: Biernacka, Patrycja, et al.
Publicado: (2023)

Predictive value of STMN1 gene promoter polymorphism (−2166T>C) in patients with advanced NSCLC treated with the combination of platinum compounds and vinorelbine
por: Mlak, Radosław, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_073mct2nifamptipmearm7n456